NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. More Details
Excellent balance sheet with concerning outlook.
Share Price & News
How has NanoString Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NSTG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NSTG's weekly volatility (11%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: NSTG exceeded the US Life Sciences industry which returned 62.3% over the past year.
Return vs Market: NSTG exceeded the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is NanoString Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StDoes NanoString Technologies (NASDAQ:NSTG) Have A Healthy Balance Sheet?
1 month ago | Simply Wall StIf You Had Bought NanoString Technologies (NASDAQ:NSTG) Stock Three Years Ago, You Could Pocket A 964% Gain Today
3 months ago | Simply Wall StHow Much Are NanoString Technologies, Inc. (NASDAQ:NSTG) Insiders Taking Off The Table?
Is NanoString Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NSTG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NSTG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NSTG is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: NSTG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSTG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NSTG is overvalued based on its PB Ratio (10.6x) compared to the US Life Sciences industry average (7.9x).
How is NanoString Technologies forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NSTG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NSTG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NSTG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NSTG's revenue (18% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: NSTG's revenue (18% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NSTG is forecast to be unprofitable in 3 years.
How has NanoString Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSTG is currently unprofitable.
Growing Profit Margin: NSTG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSTG is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare NSTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSTG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.4%).
Return on Equity
High ROE: NSTG has a negative Return on Equity (-35.86%), as it is currently unprofitable.
How is NanoString Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: NSTG's short term assets ($499.0M) exceed its short term liabilities ($37.1M).
Long Term Liabilities: NSTG's short term assets ($499.0M) exceed its long term liabilities ($200.1M).
Debt to Equity History and Analysis
Debt Level: NSTG's debt to equity ratio (56.3%) is considered high.
Reducing Debt: NSTG's debt to equity ratio has reduced from 205.4% to 56.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSTG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NSTG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.1% each year
What is NanoString Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSTG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSTG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NSTG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brad Gray (43 yo)
Mr. R. Bradley Gray, also known as Brad, has been the Chief Executive Officer and President of NanoString Technologies, Inc. since June 29, 2010. Mr. Gray worked at Genzyme Genetics, the diagnostic service...
CEO Compensation Analysis
Compensation vs Market: Brad's total compensation ($USD7.29M) is above average for companies of similar size in the US market ($USD5.13M).
Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.
Experienced Management: NSTG's management team is considered experienced (4.6 years average tenure).
Experienced Board: NSTG's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NSTG insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.5%.
NanoString Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NanoString Technologies, Inc.
- Ticker: NSTG
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.853b
- Shares outstanding: 44.58m
- Website: https://www.nanostring.com
Number of Employees
- NanoString Technologies, Inc.
- 530 Fairview Avenue North
- United States
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 23:25|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.